These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31304451)

  • 41. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma.
    Jiang LH; Hao YL; Zhu JW
    Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):282-291. PubMed ID: 30385249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.
    Schneller D; Machat G; Sousek A; Proell V; van Zijl F; Zulehner G; Huber H; Mair M; Muellner MK; Nijman SM; Eferl R; Moriggl R; Mikulits W
    Hepatology; 2011 Jul; 54(1):164-72. PubMed ID: 21452288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma.
    Sun L; Feng L; Cui J
    Diagn Pathol; 2018 Sep; 13(1):72. PubMed ID: 30219077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.
    Chen JJ; Cai N; Chen GZ; Jia CC; Qiu DB; Du C; Liu W; Yang Y; Long ZJ; Zhang Q
    Oncotarget; 2017 Mar; 8(11):17593-17609. PubMed ID: 26061710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
    Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
    Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ARF6 promotes hepatocellular carcinoma proliferation through activating STAT3 signaling.
    Hu Y; Huang Y; Xie X; Li L; Zhang Y; Zhang X
    Cancer Cell Int; 2023 Sep; 23(1):205. PubMed ID: 37716993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo.
    Rajendran P; Ong TH; Chen L; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Sharma A; Kumar AP; Hui KM; Sethi G
    Clin Cancer Res; 2011 Mar; 17(6):1425-39. PubMed ID: 21131551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 49. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer.
    Liu W; Rodgers GP
    Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
    Wang YD; Sun XJ; Yin JJ; Yin M; Wang W; Nie ZQ; Xu J
    Biomed Pharmacother; 2018 Oct; 106():134-141. PubMed ID: 29957463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma.
    Zhang L; Yang Z; Ma A; Qu Y; Xia S; Xu D; Ge C; Qiu B; Xia Q; Li J; Liu Y
    Hepatology; 2014 Jan; 59(1):178-89. PubMed ID: 23897841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells.
    Tan SM; Li F; Rajendran P; Kumar AP; Hui KM; Sethi G
    J Pharmacol Exp Ther; 2010 Jul; 334(1):285-93. PubMed ID: 20378717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
    Ohkuma R; Yada E; Ishikawa S; Komura D; Ishizaki H; Tamada K; Kubota Y; Hamada K; Ishida H; Hirasawa Y; Ariizumi H; Satoh E; Shida M; Watanabe M; Onoue R; Ando K; Tsurutani J; Yoshimura K; Yokobori T; Sasada T; Aoki T; Murakami M; Norose T; Ohike N; Takimoto M; Izumizaki M; Kobayashi S; Tsunoda T; Wada S
    PLoS One; 2020; 15(1):e0226707. PubMed ID: 31923206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
    Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
    Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC.
    Wei Y; Song Q; Zhang F; Yuan T
    Can J Gastroenterol Hepatol; 2021; 2021():5601678. PubMed ID: 34912753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
    Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
    Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.
    Ye Y; Long X; Zhang L; Chen J; Liu P; Li H; Wei F; Yu W; Ren X; Yu J
    Oncotarget; 2016 Oct; 7(43):70303-70322. PubMed ID: 27611941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
    Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
    Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma.
    Nojima H; Kuboki S; Shinoda K; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Miyazaki M
    J Hepatobiliary Pancreat Sci; 2016 Sep; 23(9):574-84. PubMed ID: 27451128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.